Martin Edelman from the Fox Chase Cancer Center in Philadelphia, PA, US discusses current treatments and unmet needs in small cell lung cancer and how research into immunotherapy, including dinutuximab and irinotecan as a second-line therapy, can contribute to treatment strategies.
1. What are the most important unmet needs in the treatment of small cell lung cancer (SCLC)? (0:11)
2. What options are available for patients who relapse or are refractory to first-line treatment? (0:38)
3. What factors impact the efficacy of and outcome after second-line treatments for SCLC? (1:29)
4. Could you tell us a little about the recent phase II/III study of dinutuximab and irinotecan for second-line treatment of SCLC? (1:56)
5. What advances have been made in the second-line therapy of SCLC using immunotherapy? (2:45)
Speaker disclosures: Martin Edelman has provided consultancy for Precision Oncology.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
